# Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

> **NCT02471183** · PHASE3 · COMPLETED · sponsor: **Actelion** · enrollment: 34 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Selexipag

## Key facts

- **NCT ID:** NCT02471183
- **Lead sponsor:** Actelion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-12
- **Primary completion:** 2016-12-05
- **Final completion:** 2016-12-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2018-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02471183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02471183, "Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02471183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*